Optomed Oyj - Other information disclosed according to the rules of the Exchange

Optomed's Board has resolved upon a new option plan

Optomed PlcStock Exchange Release17 May 2024 at 10.30, Helsinki

Optomed's Board has resolved upon a new option plan

Optomed's board of directors has resolved upon a new option plan. The resolution
is based on the authorization given by the general meeting of 10 May 2024.

Option plan 2024A:

The total number of options is 300,000 and each option entitled to one share of
the company. The options are offered to the CEO and certain key employees. The
purpose of the plan is to retain and incentifize the CEO and other key
employees. The subscription price is EUR 4.62. The subscription price is based
on the average closing prices of the last 30 trading days on Nasdaq Helsinki.
The subscription period is 1 January 2026 - 31 December 2028.

The theoretical market value of one option under the plan 2024A is approximately
EUR 2.107 per stock option and the theoretical total market value of the plan
2024A is approximately 632,100 euros in total. The theoretical market value of a
stock option has been calculated by using the Black & Scholes stock option
pricing model with the following input factors: share price EUR 5.65 euros,
subscription price EUR 4.62 risk free interest rate 2.95%, validity of stock
options approximately 3 years and volatility 55.2%.

The complete terms and conditions of the option plan 2024A are attached to this
release.

Optomed Plc

Further enquiries

Petri Salonen, Chairman, Optomed Plc, petri.salonen@optomed.com

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld cameras with software and
artificial intelligence with the aim to transform the diagnostic process of
blinding eye diseases such as rapidly increasing diabetic retinopathy. In its
business Optomed focuses on eye screening devices and software solutions related
R&D in Finland and sales through different channels in over 60 countries.

www.optomed.com

Attachments:

05173704.pdf